var data={"title":"Liposomal cytarabine (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Liposomal cytarabine (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5968?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=liposomal-cytarabine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Liposomal cytarabine (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708677\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Chemical arachnoiditis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Chemical arachnoiditis, a syndrome manifested primarily by nausea, vomiting, headache, and fever was a common adverse event in all clinical studies. If left untreated, chemical arachnoiditis may be fatal. Patients receiving intrathecal cytarabine should be treated concurrently with dexamethasone to mitigate the symptoms of chemical arachnoiditis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156098\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>DepoCyt [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156099\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>DepoCyt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156116\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156102\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> DepoCyt is no longer available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note: Initiate dexamethasone 4 mg twice daily (oral or IV) for 5 days, beginning on the day of cytarabine liposomal administration.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Lymphomatous meningitis:</b> Intrathecal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction:</i> 50 mg every 14 days for a total of 2 doses (weeks 1 and 3)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Consolidation:</i> 50 mg every 14 days for 3 doses (weeks 5, 7, and 9), followed by an additional dose at week 13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance:</i> 50 mg every 28 days for 4 doses (weeks 17, 21, 25, and 29)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990948\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988282\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156103\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5017165\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">If drug-related neurotoxicity develops, reduce dose to 25 mg. If toxicity persists, discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156079\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intrathecal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DepoCyt: 50 mg/5 mL (5 mL [DSC]) [contains cholesterol, dioleoylphosphatidylcholine (dopc), dipalmitoylphosphatidylglycerol (dppg), triolein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156063\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50960129\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">DepoCyt is no longer available in the US.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156082\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intrathecal: For intrathecal use only. Dose should be removed from vial immediately before administration (must be administered within 4 hours of removal from the vial). An in-line filter should <b>NOT</b> be used. Administer directly into the CSF via an intraventricular reservoir or by direct injection into the lumbar sac. Injection should be made slowly (over 1 to 5 minutes). Patients should lie flat for 1 hour after lumbar puncture. After administration, observe for immediate toxic reactions. Gloves should be worn during preparation and administration. If contact with skin occurs, immediately wash with soap and water; if contact with mucous membranes occurs, flush thoroughly with water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130966\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156080\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Lymphomatous meningitis:</b> Intrathecal treatment of lymphomatous meningitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156123\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine may be confused with clofarabine, Cytosar, Cytoxan, vidarabine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine liposomal may be confused with conventional cytarabine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n          <i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; Intrathecal medication should not be prepared during the preparation of any other agents</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; After preparation, store in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156070\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Peripheral edema (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chemical arachnoiditis (without dexamethasone premedication: 100%; with dexamethasone premedication: 33% to 42%; grade 4: 19% to 30%; onset: &le;5 days), headache (56%), confusion (33%), fatigue (25%), abnormal gait (23%), seizure (20% to 22%), dizziness (18%), lethargy (16%), insomnia (14%), memory impairment (14%), pain (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Dehydration (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (46%), vomiting (44%), constipation (25%), diarrhea (12%), decreased appetite (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (12%), thrombocytopenia (3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (40%), back pain (24%), limb pain (15%), neck pain (14%), arthralgia (11%), neck stiffness (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (32%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Tachycardia (9%), hypotension (8%), hypertension (6%), syncope (3%), edema (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Agitation (10%), hypoesthesia (10%), myasthenia (10%), depression (8%), anxiety (7%), peripheral neuropathy (3% to 4%), abnormal reflexes (3%), sensorimotor neuropathy (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis (2%), pruritus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypokalemia (7%), hyponatremia (7%), hyperglycemia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (9%), dysphagia (8%), anorexia (5%), hemorrhoids (3%), mucosal inflammation (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary incontinence (7%), urinary retention (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia (10%), bruise (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Hypoacusis (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (10%), cough (7%), pneumonia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, bladder disease (bladder control impaired), blindness, brain disease, cauda equina syndrome, cranial nerve palsy, deafness, drowsiness, fecal incontinence, hemiplegia, hydrocephalus, increased intracranial pressure, leukocytosis (in CSF), meningitis (infectious), myelopathy, nervous system disease (neurologic deficit), numbness, papilledema, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156085\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cytarabine or any component of the formulation; active meningeal infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156067\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Chemical arachnoiditis: <b> [US Boxed Warning]: Chemical arachnoiditis (nausea, vomiting, headache, fever) occurs commonly; may be fatal if untreated. Dexamethasone should be administered concomitantly with cytarabine (liposomal) to diminish chemical arachnoid symptoms;</b> the incidence and severity of chemical arachnoiditis is reduced with dexamethasone. If chemical arachnoiditis is suspected, exclude other possible inflammatory, infectious, or neoplastic conditions. Toxic effects may be related to a single dose or to cumulative administration and usually occur within 5 days, although may occur at any time during treatment. Monitor continuously for development of neurotoxicity; dose reduction or discontinuation may be necessary. Hydrocephalus has been reported and may be precipitated by chemical arachnoiditis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CSF component elevations: Transient elevations in CSF protein and CSF white blood cell counts have been observed following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: May cause neurotoxicity (including myelopathy), which may lead to permanent neurologic deficit (rare). The risk for neurotoxicity is increased when administered with other antineoplastic agents or with cranial/spinal irradiation. CSF flow blockage may lead to increased free cytarabine concentrations in the CSF and increases the risk for neurotoxicity; consider assessing CSF flow prior to administration. Persistent (extreme) somnolence, hemiplegia, visual disturbances (including blindness; may be total and permanent), deafness, cranial nerve palsies have been reported. Signs/symptoms of peripheral neuropathy (eg, pain, numbness, paresthesia, weakness, impaired bowel/bladder control) have also been reported. Combined neurologic features (cauda equina syndrome) have been reported in some cases. If neurotoxicity develops, reduce subsequent doses or discontinue treatment. Headache, nausea, and fever are early signs of neurotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: For intrathecal use only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intrathecal safety: Intrathecal medications should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only. Delivery of intrathecal medications to the patient should only be with other medications intended for administration into the central nervous system (Jacobson, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299115\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156072\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9500&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156075\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156086\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproductive studies with conventional cytarabine. Conventional cytarabine has been associated with fetal malformations when given as a component of systemic combination chemotherapy during the first trimester. Systemic exposure following intrathecal administration of cytarabine liposomal is negligible; however, women of childbearing potential should avoid becoming pregnant during treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4936523\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cytarabine (liposomal) is excreted in breast milk; the systemic exposure following intrathecal administration of cytarabine (liposomal) is negligible. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue cytarabine (liposomal) or to discontinue breast-feeding, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156077\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor closely for signs of an immediate reaction; chemical arachnoiditis; neurotoxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156066\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cytarabine liposomal is a sustained-release formulation of the active ingredient cytarabine, an antimetabolite which acts through inhibition of DNA synthesis and is cell cycle-specific for the S phase of cell division. Cytarabine is converted intracellularly to its active metabolite cytarabine-5&rsquo;-triphosphate (ara-CTP). Ara-CTP also appears to be incorporated into DNA and RNA; however, the primary action is inhibition of DNA polymerase, resulting in decreased DNA synthesis and repair. The liposomal formulation allows for gradual release, resulting in prolonged exposure. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156084\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Systemic exposure following intrathecal administration is negligible since transfer rate from CSF to plasma is slow </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, CSF: 6 to 82 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, CSF: Intrathecal: &lt;1 hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323089\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (DepoCyt Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $3556.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156087\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Depocyt (BB);</li>\n      <li>Depocyte (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IS, IT, LT, MT, NL, NO, PL, PT, RO, RU, SE, SI, SK, TR);</li>\n      <li>DepoCyte (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cole BF, Glantz MJ, Jaeckle KA, et al, &ldquo;Quality-of-Life-Adjusted Survival Comparison of Sustained-Release Cytosine Arabinoside Versus Intrathecal Methotrexate for Treatment of Solid Tumor Neoplastic Meningitis,&rdquo; <i>Cancer</i>, 2003, 97(12):3053-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-cytarabine-united-states-not-available-drug-information/abstract-text/12784341/pubmed\" target=\"_blank\" id=\"12784341\">12784341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depocyt (cytarabine liposome injection) (prescribing information). San Diego, California: Pacira Pharmaceuticals, Inc; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Marco JA, Panizo C, Garcia ES, et al, &ldquo;Efficacy and Safety of Liposomal Cytarabine in Lymphoma Patients With Central Nervous System Involvement From Lymphoma,&rdquo; <i>Cancer</i>, 2009, 115(9):1892-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-cytarabine-united-states-not-available-drug-information/abstract-text/19235254/pubmed\" target=\"_blank\" id=\"19235254\">19235254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glantz MJ, LaFollette S, Jaeckle KA, et al, &ldquo;Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis,&rdquo; <i>J Clin Oncol</i>, 1999, 17(10):3110-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-cytarabine-united-states-not-available-drug-information/abstract-text/10506606/pubmed\" target=\"_blank\" id=\"10506606\">10506606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jabbour E, O&rsquo;Brien S, Kantarjian H, et al, &ldquo;Neurologic Complications Associated With Intrathecal Liposomal Cytarabine in Combination With High-Dose Methotrexate and Cytarabine to Patients With Acute Lymphocytic Leukemia,&rdquo; <i>Blood</i>, 2007, 109(8):3214-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-cytarabine-united-states-not-available-drug-information/abstract-text/17209054/pubmed\" target=\"_blank\" id=\"17209054\">17209054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &ldquo;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&rdquo; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-cytarabine-united-states-not-available-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaeckle KA, Batchelor T, O'Day SJ, et al, &ldquo;An Open Label Trial of Sustained-Release Cytarabine (DepoCyt) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis,&rdquo; <i>J Neurooncol</i>, 2002, 57(3):231-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-cytarabine-united-states-not-available-drug-information/abstract-text/12125986/pubmed\" target=\"_blank\" id=\"12125986\">12125986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spina M, Chimienti E, Martellotta F, et al, &ldquo;Phase 2 Study of Intrathecal, Long-Acting Liposomal Cytarabine in the Prophylaxis of Lymphomatous Meningitis in Human Immunodeficiency Virus-Related non-Hodgkin Lymphoma,&rdquo; <i>Cancer</i>, 2010, 116(6):1495-501.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-cytarabine-united-states-not-available-drug-information/abstract-text/20108270/pubmed\" target=\"_blank\" id=\"20108270\">20108270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9500 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708677\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156098\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156099\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F156116\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156102\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990948\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988282\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156103\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F5017165\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156079\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F156063\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50960129\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F156082\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130966\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F156080\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156123\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156070\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156085\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156067\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299115\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156072\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156075\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156086\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4936523\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F156077\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156066\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F156084\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323089\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F156087\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9500|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=liposomal-cytarabine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Liposomal cytarabine (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}